Embecta Corp. (NASDAQ:EMBC) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of Embecta Corp. (NASDAQ:EMBC) have been given a consensus recommendation of “Reduce” by the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $11.00.

A number of brokerages recently issued reports on EMBC. Bank of America lowered their price target on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a report on Monday, May 18th. Wall Street Zen cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. BTIG Research lowered shares of Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Finally, Weiss Ratings cut Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, May 6th.

Hedge Funds Weigh In On Embecta

A number of hedge funds have recently bought and sold shares of EMBC. Walleye Capital LLC acquired a new position in Embecta during the first quarter worth $7,013,000. SG Americas Securities LLC grew its position in shares of Embecta by 138.4% in the first quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company’s stock valued at $9,184,000 after purchasing an additional 603,106 shares during the period. Ameriprise Financial Inc. grew its position in shares of Embecta by 439.1% in the second quarter. Ameriprise Financial Inc. now owns 709,849 shares of the company’s stock valued at $6,878,000 after purchasing an additional 578,174 shares during the period. Jefferies Financial Group Inc. increased its stake in shares of Embecta by 24.9% during the fourth quarter. Jefferies Financial Group Inc. now owns 2,354,971 shares of the company’s stock worth $27,977,000 after purchasing an additional 470,096 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of Embecta by 200.8% during the fourth quarter. UBS Group AG now owns 630,994 shares of the company’s stock worth $7,496,000 after purchasing an additional 421,254 shares in the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

More Embecta News

Here are the key news stories impacting Embecta this week:

• Neutral Sentiment: The securities case covers investors who purchased Embecta shares between November 25, 2025, and May 4, 2026. Several firms are seeking lead-plaintiff applicants, with an August 17, 2026 deadline. These notices primarily repeat previously reported litigation developments rather than introduce a new operating update. Rosen Embecta class action deadline notice
• Neutral Sentiment: Embecta is also scheduled to report quarterly earnings, making the upcoming results and management commentary important catalysts. Investors will likely focus on insulin pen-needle demand, revenue guidance, dividend policy, and whether the company can meet its fiscal 2026 EPS target of $1.55 to $1.75.
• Negative Sentiment: The concentration of new investor-law-firm announcements is increasing concerns about potential legal costs, damages, management credibility, and further scrutiny of Embecta’s disclosures. The litigation adds to existing fundamental worries, including the latest reported revenue decline, an earnings miss, and sharply reduced guidance. Hagens Berman Embecta investigation

Embecta Trading Down 0.5%

Embecta stock opened at $3.64 on Friday. Embecta has a 12 month low of $2.77 and a 12 month high of $15.55. The stock’s 50 day simple moving average is $3.29 and its two-hundred day simple moving average is $6.97. The firm has a market cap of $215.96 million, a PE ratio of 1.92 and a beta of 0.83.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.15). The firm had revenue of $221.80 million for the quarter, compared to analyst estimates of $235.67 million. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.Embecta’s revenue for the quarter was down 14.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.70 EPS. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. On average, equities research analysts forecast that Embecta will post 1.62 EPS for the current year.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.